{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:32:51Z","timestamp":1791264771407,"version":"4.1.0"},"reference-count":116,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Immune checkpoint inhibitors (ICI) are now widely used in the treatment of many cancers, and currently represent the standard of care for multiple malignancies. These agents enhance the T cell immune response to target cancer tissues, and have demonstrated considerable benefits for cancer outcomes. However, despite these improved outcomes, there are important kidney immune-related adverse events (iRAEs) associated with ICI. Acute tubulo-interstitial nephritis remains the most frequent kidney iRAE, however glomerular lesions and electrolytes disturbances are increasingly being recognized and reported. In this review, we summarize clinical features and identify risk factors for kidney iRAEs, and discuss the current understanding of pathophysiologic mechanisms. We highlight the evidence basis for guideline-recommended management of ICI-related kidney injury as well as gaps in current knowledge. We advocate for judicious use of kidney biopsy to identify ICI-associated kidney injury, and early use of corticosteroid treatment where appropriate. Selected patients may also be candidates for re-challenge with ICI therapy after a kidney iRAE, in view of current data on recurrent rates of kidney injury. Risk of benefits of re-challenge must be considered on an individual considering patient preferences and prognosis. Lastly, we review current knowledge of ICI use in the setting of patients with end-stage kidney disease, including kidney transplant recipients and those receiving dialysis, which suggest that these patients should not be summarily excluded from the potential benefits of these cancer therapies.<\/jats:p>","DOI":"10.1093\/ckj\/sfad014","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T11:20:11Z","timestamp":1675077611000},"page":"939-951","source":"Crossref","is-referenced-by-count":30,"title":["Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events"],"prefix":"10.1093","volume":"16","author":[{"given":"Avinash","family":"Rao Ullur","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University Health Network, University of Toronto , Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, CHU de Qu\u00e9bec, Universit\u00e9 Laval , Quebec City, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyne","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Department of Medicine, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5046","authenticated-orcid":false,"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University Health Network, University of Toronto , Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"2023053100310440200_bib1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2023053100310440200_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2023053100310440200_bib3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2023053100310440200_bib4","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","article-title":"Ipilimumab granulomatous interstitial nephritis","volume":"22","author":"Thajudeen","year":"2015","journal-title":"Am J Ther"},{"key":"2023053100310440200_bib5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053100310440200_bib6","doi-asserted-by":"crossref","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Munoz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CJI.0000000000000338","article-title":"Incidence and prediction of immune checkpoint inhibitor-related nephrotoxicity","volume":"44","author":"Sorah","year":"2021","journal-title":"J Immunother"},{"key":"2023053100310440200_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2023053100310440200_bib9","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.kint.2022.07.019","article-title":"Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer","volume":"102","author":"Gupta","year":"2022","journal-title":"Kidney Int"},{"key":"2023053100310440200_bib11","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"2023053100310440200_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nrm973","article-title":"Receptor downregulation and multivesicular-body sorting","volume":"3","author":"Katzmann","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023053100310440200_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"2023053100310440200_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2023053100310440200_bib15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges","volume":"8","author":"Kyi","year":"2016","journal-title":"Immunotherapy"},{"key":"2023053100310440200_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2023053100310440200_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"2023053100310440200_bib18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"2023053100310440200_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023053100310440200_bib20","first-page":"9","article-title":"Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials","volume":"10","author":"Wolchok","year":"2010","journal-title":"Cancer Immun"},{"key":"2023053100310440200_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2023053100310440200_bib22","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023053100310440200_bib23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ni.2037","article-title":"The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells","volume":"12","author":"Ise","year":"2011","journal-title":"Nat Immunol"},{"key":"2023053100310440200_bib24","doi-asserted-by":"crossref","first-page":"e001198","DOI":"10.1136\/jitc-2020-001198","article-title":"Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma","volume":"8","author":"Patel","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10637-017-0534-0","article-title":"Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience","volume":"36","author":"Fujii","year":"2018","journal-title":"Invest New Drugs"},{"key":"2023053100310440200_bib26","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023053100310440200_bib27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"2023053100310440200_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023053100310440200_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"2023053100310440200_bib30","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2023053100310440200_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"key":"2023053100310440200_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2018.05.015","article-title":"Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report","volume":"122","author":"Takahashi","year":"2018","journal-title":"Lung Cancer"},{"key":"2023053100310440200_bib33","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med"},{"key":"2023053100310440200_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023053100310440200_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"2023053100310440200_bib37","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ckj\/sfaa008","article-title":"Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience","volume":"14","author":"Oleas","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023053100310440200_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2023053100310440200_bib39","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2023053100310440200_bib40","doi-asserted-by":"crossref","first-page":"662731","DOI":"10.3389\/fonc.2021.662731","article-title":"Comparative risk of renal adverse events in patients receiving immune checkpoint inhibitors: a Bayesian network meta-analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"2023053100310440200_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.acr.2019.03.002","article-title":"From immune checkpoints to vaccines: the past, present and future of cancer immunotherapy","volume":"143","author":"Osipov","year":"2019","journal-title":"Adv Cancer Res"},{"key":"2023053100310440200_bib42","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2023053100310440200_bib43","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023053100310440200_bib44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"2023053100310440200_bib45","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","article-title":"Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"69","author":"Peng","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2023053100310440200_bib46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jjco\/hyy201","article-title":"Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies","volume":"49","author":"Nakamura","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2023053100310440200_bib47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"key":"2023053100310440200_bib48","doi-asserted-by":"crossref","first-page":"14039","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"},{"key":"2023053100310440200_bib49","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"2023053100310440200_bib50","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"key":"2023053100310440200_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"2023053100310440200_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib53","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","article-title":"C-reactive protein as an early marker of immune-related adverse events","volume":"145","author":"Abolhassani","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2023053100310440200_bib54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"2023053100310440200_bib55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clim.2019.06.005","article-title":"Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury","volume":"205","author":"Sun","year":"2019","journal-title":"Clin Immunol"},{"key":"2023053100310440200_bib56","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023053100310440200_bib57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"2023053100310440200_bib58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12149-007-0012-4","article-title":"FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues","volume":"21","author":"Minamimoto","year":"2007","journal-title":"Ann Nucl Med"},{"key":"2023053100310440200_bib59","first-page":"155","article-title":"Positron emission tomography combined with computed tomography (PET-CT) as a new diagnostic tool for acute tubulointerstitial nephritis (AIN) in oliguric or haemodialysed patients","volume":"3","author":"Katagiri","year":"2010","journal-title":"NDT Plus"},{"key":"2023053100310440200_bib60","doi-asserted-by":"crossref","first-page":"100552","DOI":"10.1016\/j.xkme.2022.100552","article-title":"Acute interstitial nephritis on positron-emission tomography-computed tomography imaging","volume":"4","author":"Miao","year":"2022","journal-title":"Kidney Med"},{"key":"2023053100310440200_bib61","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"Qualls","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib62","doi-asserted-by":"crossref","first-page":"e002292","DOI":"10.1136\/jitc-2020-002292","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy: single center experience of management and drug rechallenge","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney360"},{"key":"2023053100310440200_bib64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"2023053100310440200_bib65","doi-asserted-by":"crossref","first-page":"gfac217","DOI":"10.1093\/ndt\/gfac217","article-title":"AA amyloidosis associated with cancers","author":"Bharati","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023053100310440200_bib66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/2399369320907598","article-title":"Immune checkpoint inhibitor\u2013associated renal amyloid A amyloidosis: a case series and review of the literature","volume":"4","author":"Lapman","year":"2020","journal-title":"J Onco-Nephrol"},{"key":"2023053100310440200_bib67","article-title":"Management of Immunotherapy-Related Toxicities (Version 1.2022)","author":"Network","year":"2022","journal-title":"NCCN Clinical Practice Guidelines in Oncology. [Internet]."},{"key":"2023053100310440200_bib68","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib69","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s11864-022-00995-9","article-title":"Immune checkpoint inhibitor rechallenge after prior immune toxicity","volume":"23","author":"Bylsma","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2023053100310440200_bib70","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study","volume":"111","author":"Kitchlu","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2023053100310440200_bib71","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.ajkd.2008.11.034","article-title":"Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis","volume":"53","author":"Coca","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2023053100310440200_bib72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ki.2011.405","article-title":"Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury","volume":"81","author":"Bucaloiu","year":"2012","journal-title":"Kidney Int"},{"key":"2023053100310440200_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneph.2012.280","article-title":"Chronic kidney disease following acute kidney injury-risk and outcomes","volume":"9","author":"Leung","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2023053100310440200_bib74","article-title":"Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials","author":"Peron","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2023053100310440200_bib75","doi-asserted-by":"crossref","first-page":"e002535","DOI":"10.1136\/jitc-2021-002535","article-title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis","volume":"9","author":"Tarhini","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib76","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12032-010-9606-0","article-title":"Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy","volume":"28","author":"Harmankaya","year":"2011","journal-title":"Med Oncol"},{"key":"2023053100310440200_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.9037","article-title":"Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity","volume":"27","author":"Amin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023053100310440200_bib78","first-page":"887","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors","volume":"37","author":"Garcia-Carro","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023053100310440200_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2021.07.031","article-title":"Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors","volume":"157","author":"Seethapathy","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023053100310440200_bib80","article-title":"The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis","author":"Kanbay","year":"2022","journal-title":"Clin Kidney J"},{"key":"2023053100310440200_bib81","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"2023053100310440200_bib82","doi-asserted-by":"crossref","first-page":"102974","DOI":"10.1016\/j.critrevonc.2020.102974","article-title":"Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis","volume":"151","author":"Cantini","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2023053100310440200_bib83","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023053100310440200_bib84","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12032-010-9794-7","article-title":"Hyponatremia associated with ipilimumab-induced hypophysitis","volume":"29","author":"Barnard","year":"2012","journal-title":"Med Oncol"},{"key":"2023053100310440200_bib85","first-page":"e7625","article-title":"Nivolumab induced adrenal insufficiency: rare side-effect of a new anti-cancer therapy - immune-checkpoint inhibitors","volume":"12","author":"Rai","year":"2020","journal-title":"Cureus"},{"key":"2023053100310440200_bib86","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/postgradmedj-2019-137297","article-title":"Acute hyponatremia from immune checkpoint inhibitor therapy for non-small cell lung cancer","volume":"96","author":"Desikan","year":"2020","journal-title":"Postgrad Med J"},{"key":"2023053100310440200_bib87","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.kint.2020.05.015","article-title":"Rondon-Berrios H. Hyponatremia in the cancer patient","volume":"98","author":"Workeneh","year":"2020","journal-title":"Kidney Int"},{"key":"2023053100310440200_bib88","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023053100310440200_bib89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023053100310440200_bib90","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.kint.2021.06.001","article-title":"Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System","volume":"100","author":"Wanchoo","year":"2021","journal-title":"Kidney Int"},{"key":"2023053100310440200_bib91","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: a comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"World J Clin Cases"},{"key":"2023053100310440200_bib92","first-page":"7896749","article-title":"Ipilimumab- and nivolumab-induced colitis causing severe hypokalemia and QTc prolongation","volume":"2019","author":"Anson","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"2023053100310440200_bib93","first-page":"5063405","article-title":"Hypokalemic paralysis secondary to immune checkpoint inhibitor therapy","volume":"2017","author":"Balakrishna","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"2023053100310440200_bib94","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.xkme.2020.05.015","article-title":"Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-a report of 3 cases","volume":"2","author":"Herrmann","year":"2020","journal-title":"Kidney Med"},{"key":"2023053100310440200_bib95","first-page":"e7686","article-title":"Immune Checkpoint inhibitor-induced Fanconi syndrome","volume":"12","author":"Farid","year":"2020","journal-title":"Cureus"},{"key":"2023053100310440200_bib96","first-page":"8408015","article-title":"Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy","volume":"2018","author":"El Bitar","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"2023053100310440200_bib97","first-page":"7406911","article-title":"A rare presentation of checkpoint inhibitor induced distal RTA","volume":"2021","author":"Doodnauth","year":"2021","journal-title":"Case Rep Oncol Med"},{"key":"2023053100310440200_bib98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ckj\/sfz051","article-title":"A new expression of immune checkpoint inhibitors' renal toxicity: when distal tubular acidosis precedes creatinine elevation","volume":"13","author":"Charmetant","year":"2020","journal-title":"Clin Kidney J"},{"key":"2023053100310440200_bib99","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2005.01.005","article-title":"PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis","volume":"115","author":"Ding","year":"2005","journal-title":"Clin Immunol"},{"key":"2023053100310440200_bib100","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.14671121","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053100310440200_bib101","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/j.seminoncol.2015.09.006","article-title":"Parathyroid hormone-related peptide-linked hypercalcemia in a melanoma patient treated with ipilimumab: hormone source and clinical and metabolic correlates","volume":"42","author":"Mills","year":"2015","journal-title":"Semin Oncol"},{"key":"2023053100310440200_bib102","doi-asserted-by":"crossref","first-page":"769","DOI":"10.21873\/invivo.11129","article-title":"Rapid progressive disease after nivolumab therapy in three patients with metastatic renal cell carcinoma","volume":"31","author":"Kobari","year":"2017","journal-title":"In Vivo"},{"key":"2023053100310440200_bib103","doi-asserted-by":"crossref","first-page":"358","DOI":"10.14740\/jocmr3257w","article-title":"Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma","volume":"10","author":"Takebayashi","year":"2018","journal-title":"J Clin Med Res"},{"key":"2023053100310440200_bib104","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ndt\/gfaa326","article-title":"Immune checkpoint inhibitor-associated hypercalcaemia","volume":"37","author":"Izzedine","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023053100310440200_bib105","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023053100310440200_bib106","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA"},{"key":"2023053100310440200_bib107","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/j.ajkd.2020.02.451","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients on dialysis: a retrospective case series","volume":"76","author":"Strohbehn","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023053100310440200_bib108","doi-asserted-by":"crossref","first-page":"584834","DOI":"10.3389\/fonc.2020.584834","article-title":"Safety and efficacy of immune checkpoint inhibitors for patients with metastatic urothelial carcinoma and end-stage renal disease: experiences from real-world practice","volume":"10","author":"Kuo","year":"2020","journal-title":"Front Oncol"},{"key":"2023053100310440200_bib109","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"2023053100310440200_bib110","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"2023053100310440200_bib111","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transplant"},{"key":"2023053100310440200_bib112","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2023053100310440200_bib113","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1111\/ajt.15071","article-title":"Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients","volume":"18","author":"Zehou","year":"2018","journal-title":"Am J Transplant"},{"key":"2023053100310440200_bib114","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"key":"2023053100310440200_bib115","doi-asserted-by":"crossref","first-page":"574271","DOI":"10.3389\/fimmu.2020.574271","article-title":"The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?","volume":"11","author":"Franzin","year":"2020","journal-title":"Front Immunol"},{"key":"2023053100310440200_bib116","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad014\/49880901\/sfad014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/6\/939\/50462164\/sfad014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/6\/939\/50462164\/sfad014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T04:33:00Z","timestamp":1685507580000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/6\/939\/7008857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":116,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,1,28]]},"published-print":{"date-parts":[[2023,5,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad014","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,1,28]]}}}